Date: Wednesday, 28/09/2022
Time: 1pm
To: Standing Committee
At: [Redacted]
Subject: AWERB Standing Committee
Our Ref: Doc. UBS.AWERB.28.09.22

In attendance:

Scientists in attendance for 1a) N/A, 1b) N/A, 1c) N/A & 1d) N/A

Apologies:

Minutes:

1. Project Licences

(a) New licence:

The committee discussed the following:

- The removal of specific words that are not appropriate in the Non-Technical Summary.
- Further information included in the Benefits sections.
- The inclusion of reference to scoring systems in the Refinement section.
- The recommendation that the applicant uses the most up to date template for Protocols 1 to 4.
- Further specificity in regards to the adverse effects and humane end points needed in the actual steps of Protocols 5 to 12, not the overall protocol.
- Further information in regards to specific adverse effects that may be seen and the appropriate humane endpoints that will be applied in Protocols 5 to 12.
- Methods for calculating weight loss need to be consistent across all protocols and if they need to vary an explanation needs to be provided.
- Further detail required in regards to specific monitoring and clinical signs expected in regards to different types of tumours.
- Age-associated endpoints that are only required in the ageing steps.
- Simplification required in the Animal Experience sections.
- Further revision required in regards to the general humane endpoints in the Animal Experience section.
- The recommendation that the applicant amends Protocol 5 with the advice given and return it to their Project Support Team to review before working on the remaining protocols.

The committee agreed changes were required before a draft is submitted to the Home Office.

(b) New Licence:

The committee discussed the following:
- Consideration given to whether specific adverse effects are appropriate in regards to all the protocols.
- The inclusion of juvenile in the life stages of animals used in Protocol 1.
- Further clarification in regards to the wording in Step 6 of Protocol 2.
- If the minipump is to be an administration route a step to implant it needs including in Step 9 of Protocol 2.
- Further clarification around how animals will be considered for reuse.
- Further information around the vectors mentioned.

The committee agreed minor changes are needed before a draft is submitted to the Home Office.

(c) New Licence: [Redacted]

The committee discussed the following:
- Further detail in regards to how the in-vitro work translates to the in-vivo work in regards to choosing the genes of interest.
- Further information in regards to the pathogenic organisms that the applicant plans to use throughout the Project.
- The recommendation that the applicant checks the animal numbers are correct in the Reduction section.
- Further detail required in regards to the adverse effects expected in Protocols 5 and 6.
- The inclusion of recovery time points associated with specific adverse effects and further information around at what point the humane endpoint is applied.
- Revision of specific text in regards to all adverse effects.
- Further consistency required in regards to administration routes in the dosing tables.
- Further consideration given to adverse effects in step 3 of Protocol 5.

The committee agreed changes were needed before a draft is submitted to the Home Office.

(d) New Licence: [Redacted] (was also in attendance)

The committee discussed the following:
- Anonymisation of the non-technical area as this will be available to the public.
- Further information around specific procedures planned.
- Further information in regards to the funding.
- Further consistency required in regards to anaesthetic codes.
- Further specificity required in regards to adverse effects and humane endpoints as well as the recommendation that score sheets are referenced in Step 1 of Protocol 5.
- The inclusion of topical treatments in regards to monitoring and control methods in Step 1 of Protocol 5 and the inclusion of a humane endpoint associated with this.
- The suggestion that specific sections are removed if they are not appropriate in regards to the General humane endpoints of Protocol 5.
- Further clarification required in regards to specific procedures in the Animal Experience section of Protocol 6.

The committee agreed changes were needed before a draft is submitted to the Home Office.

2. Retrospective Reviews
(a) None
3. Minutes of last meeting 31/08/22
The minutes were approved.

5. Minutes of the AWERB 3Rs Committee 03/08/33
The minutes were noted.

7. Matters arising from the minutes and AOB
Non-Regulated Procedure request:  – The AWERB committee reviewed the Non-Regulated Procedure request and had no comments to add. The committee signed off on this request.

Non-Regulated Procedure request:  – The AWERB committee reviewed the Non-Regulated Procedure request and asked for further information in regards to the method used for specific procedures. Once this information has been provided the request will be signed off by the committee.

Non-Regulated Procedure request:  – The AWERB committee reviewed the Non-Regulated Procedure request and had no comments to add. The committee signed off on this request.

Non-Regulated Procedure request:  – The AWERB committee reviewed the Non-Regulated Procedure request and considered whether the proposal should be considered as Clinical Research. The committee recommended that the applicant submits a revised document, removing a lot of the detail that is no longer relevant and only consisting of what they would like to do. The committee agreed at this point they would seek further advice from the Home Office for the most appropriate way for the work to be achieved.

submitted by the  was noted by the committee.

8. List items of note

Date of next meeting: 26/10/22